Taysha Gene Therapies Inc (TSHA)
2.57
-0.01
(-0.39%)
USD |
NASDAQ |
May 03, 16:00
2.575
0.00 (0.00%)
After-Hours: 20:00
Taysha Gene Therapies Cash from Operations (TTM): -73.02M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -73.02M |
| September 30, 2023 | -42.19M |
| June 30, 2023 | -53.05M |
| March 31, 2023 | -67.64M |
| December 31, 2022 | -88.39M |
| September 30, 2022 | -143.36M |
| June 30, 2022 | -146.48M |
| Date | Value |
|---|---|
| March 31, 2022 | -135.95M |
| December 31, 2021 | -117.04M |
| September 30, 2021 | -96.63M |
| June 30, 2021 | -71.42M |
| March 31, 2021 | -51.06M |
| December 31, 2020 | -30.73M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-146.48M
Minimum
Jun 2022
-30.73M
Maximum
Dec 2020
-85.92M
Average
-73.02M
Median
Dec 2023
Cash from Operations (TTM) Benchmarks
| Aquestive Therapeutics Inc | -6.38M |
| Lifecore Biomedical Inc | -34.46M |
| Relmada Therapeutics Inc | -51.66M |
| ACADIA Pharmaceuticals Inc | 16.70M |
| Cyclacel Pharmaceuticals Inc | -16.11M |